Key Documents

Methotrexate hydrate

Name: Methotrexate hydrate
Brand: SIGMA
Price: 71.1 CHF

powder, ≥98% (HPLC)

Synonym(s):

4-Amino-10-methylfolic acid hydrate, L-4-Amino-N¹⁰-methylpteroylglutamic acid hydrate, L-Amethopterin hydrate, Antifolan hydrate, MTX hydrate, Methylaminopterin hydrate

Select a Size

Change View

Pack Size	Availability	Price
10 mg	Check Cart for Availability	CHF 71.10
25 mg	Check Cart for Availability	CHF 75.30
100 mg	Check Cart for Availability	CHF 167.00
1 g	Check Cart for Availability	CHF 1’390.00
500 mg	Check Cart for Availability	CHF 1’560.00

About This Item

Empirical Formula (Hill Notation):

C₂₀H₂₂N₈O₅ · xH₂O

CAS Number:

133073-73-1

Molecular Weight:

454.44 (anhydrous basis)

UNSPSC Code:

12352202

PubChem Substance ID:

57653876

NACRES:

NA.77

MDL number:

MFCD00150847

CHF 71.10

Check Cart for Availability

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Product Name

Methotrexate hydrate, ≥98% (HPLC), powder

biological source

synthetic (organic)

Quality Level

200

assay

≥98% (HPLC)

form

powder

color

, yellow to very dark yellow to very dark orange

mp

185-204 °C

solubility

H₂O: insoluble

storage temp.

−20°C

SMILES string

[H]O[H].CN(Cc1cnc2nc(N)nc(N)c2n1)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O

Looking for similar products? Visit Product Comparison Guide

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item	M8407	M7824	06563
Sigma-Aldrich A6770 Methotrexate hydrate	Sigma-Aldrich M8407 Methotrexate hydrate	SAFC M7824 Methotrexate	Sigma-Aldrich 06563 Methotrexate hydrate
assay ≥98% (HPLC)	assay ≥98% (HPLC)	assay -	assay ≥99.0% (sum of enantiomers, HPLC)
biological source synthetic (organic)	biological source -	biological source synthetic	biological source synthetic
Gene Information human ... DHFR(1719)	Gene Information human ... DHFR(1719)	Gene Information human ... DHFR(1719)	Gene Information human ... DHFR(1719)
Quality Level 200	Quality Level 200	Quality Level 400	Quality Level 200
form powder	form powder	form powder	form powder or crystals
solubility H₂O: insoluble	solubility H₂O: insoluble	solubility -	solubility water: insoluble

Application

Potent inhibitor of dihydrofolate reductase and agent for antitumor studies. Use to inhibit dihydrofolate reductase in DHFR-based protein expression systems.

Potent inhibitor of dihydrofolate reductase and agent for antitumor studies. Use to inhibit dihydrofolate reductase in DHFR-based protein expression systems. Also effective in treatment of pyrimethamine-resistant Plasmodium vivax malaria parasites.

Potent inhibitor of dihydrofolate reductase and agent for antitumor studies. Use to inhibit dihydrofolate reductase in DHFR-based protein expression systems. Also shows immunosuppressive effects in, e.g., rheumatoid arthritis.

related product

Product No.

Description

Pricing

D6566

Dihydrofolate Reductase human, ≥80% (SDS-PAGE), recombinant, expressed in E. coli, ≥1 units/mg protein

pictograms

GHS06,GHS08

signalword

Danger

hcodes

H301,H315,H319,H360FD

pcodes

P202 - P264 - P280 - P301 + P310 - P302 + P352 - P305 + P351 + P338

Hazard Classifications

Acute Tox. 3 Oral - Eye Irrit. 2 - Repr. 1B - Skin Irrit. 2

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Targeting folate receptor beta on monocytes/macrophages renders rapid inflammation resolution independent of root causes.

Yingjuan J Lu et al.

Cell reports. Medicine, 2(10), 100422-100422 (2021-11-11)

Provoked by sterile/nonsterile insults, prolonged monocyte mobilization and uncontrolled monocyte/macrophage activation can pose imminent or impending harm to the affected organs. Curiously, folate receptor beta (FRβ), with subnanomolar affinity for the vitamin folic acid (FA), is upregulated during immune activation

Next-Generation Intestinal Toxicity Model of Human Embryonic Stem Cell-Derived Enterocyte-Like Cells.

Bokyeong Ryu et al.

Frontiers in veterinary science, 8, 587659-587659 (2021-10-05)

The gastrointestinal tract is the most common exposure route of xenobiotics, and intestinal toxicity can result in systemic toxicity in most cases. It is important to develop intestinal toxicity assays mimicking the human system; thus, stem cells are rapidly being

Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients.

Josef Singer et al.

Molecular cancer therapeutics, 13(7), 1777-1790 (2014-04-24)

Passive immunotherapy with monoclonal antibodies represents a cornerstone of human anticancer therapies, but has not been established in veterinary medicine yet. As the tumor-associated antigen EGFR (ErbB-1) is highly conserved between humans and dogs, and considering the effectiveness of the

Ceria-based nanotheranostic agent for rheumatoid arthritis.

Irina Kalashnikova et al.

Theranostics, 10(26), 11863-11880 (2020-11-19)

Rheumatoid arthritis (RA) is an autoimmune disease that affects 1-2% of the human population worldwide, and effective therapies with targeted delivery for local immune suppression have not been described. We address this problem by developing a novel theranostic nanoparticle for

Drugging the Folate Pathway in Mycobacterium tuberculosis: The Role of Multi-targeting Agents.

Behnoush Hajian et al.

Cell chemical biology, 26(6), 781-791 (2019-04-02)

The folate biosynthetic pathway offers many druggable targets that have yet to be exploited in tuberculosis therapy. Herein, we have identified a series of small molecules that interrupt Mycobacterium tuberculosis (Mtb) folate metabolism by dual targeting of dihydrofolate reductase (DHFR), a

View All Related Papers

Articles

Folic Acid Metabolism in Cancer

Biofiles reviews innovative technologies for cancer research, reflecting the complexity of the disease.

Folic Acid Metabolism in Cancer

Cancer research innovations address the complexity of the disease, providing advanced technologies for varied applications.

Global Trade Item Number

SKU	GTIN
A6770-500MG	04061832938851
A6770-25MG	04061833382820
A6770-1G	04061833382813
A6770-10MG	04061833382806
A6770-100MG	04061833382790

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service